BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models

This is early-stage research news.

Risk flags

• ●Lack of quantitative data: The announcement provides no numerical results or peer-r

Announcement summary

BriaCell Therapeutics Corp. is presenting positive data from its preclinical Bria-OTS+ platform at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The event is taking place April 17–22 at the San Diego Convention Center in San Diego, California. The company is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care. The announcement highlights the company's ongoing research and engagement with the scientific community. Investors may note the company's participation in a major industry conference and the presentation of positive preclinical data.

Disagree with this article?